A first-generation tau tracer called [11C]PBB3 was developed in 2014, and shown to be effective in patients with AD and non-AD tauopathies for observing tau pathology in preclinical evaluations (Hashimoto et al., 2014; Ono et al., 2017). Here, MAPT is linked to Alzheimer disease.